Date published: 2025-10-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

FAM57A Inhibitors

The chemical class FAM57A Inhibitors refers to a diverse group of compounds primarily involved in the modulation of lipid metabolism and homeostasis. These chemicals do not directly target FAM57A but can influence its activity by altering the intracellular environment, particularly lipid concentration, composition, and trafficking, which are critical for the function of lipid-associated proteins like FAM57A. For example, Triacsin C and Etomoxir disrupt fatty acid activation and transport, respectively, which can lead to changes in the lipid species that FAM57A may interact with or regulate. Orlistat's action on lipases may reduce the intracellular influx of fatty acids from dietary sources, thereby affecting lipid pools relevant to FAM57A's function. ML236B, Fenofibrate, and Gemfibrozil act on different aspects of lipid synthesis and metabolism, with the potential to modify the lipid landscape that FAM57A encounters within the cell. Compounds such as Nicotinic acid and Chloroquine impact lipolysis and lysosomal lipid degradation, respectively, which could impact the availability of lipid substrates or intermediates that FAM57A handles. Filipin and U18666A, by interacting with cholesterol, can alter membrane properties and potentially disrupt the domains where FAM57A operates. GW4869 targets sphingolipid metabolism, which is tightly linked to various lipid signaling pathways and could, therefore, indirectly affect FAM57A's role in these processes.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Triacsin C Solution in DMSO

76896-80-5sc-200574
sc-200574A
100 µg
1 mg
$149.00
$826.00
14
(1)

Inhibits long-chain acyl-CoA synthetase, potentially reducing fatty acid availability for lipid synthesis that FAM57A may regulate.

(+)-Etomoxir sodium salt

828934-41-4sc-215009
sc-215009A
5 mg
25 mg
$148.00
$496.00
3
(2)

Inhibits carnitine palmitoyltransferase-1 (CPT-1), potentially limiting fatty acid β-oxidation and affecting lipid pools that FAM57A is associated with.

rac Perhexiline Maleate

6724-53-4sc-460183
10 mg
$184.00
(0)

Inhibits mitochondrial carnitine/acylcarnitine carrier proteins, which may alter fatty acid utilization and indirectly impact FAM57A's function.

Lipase Inhibitor, THL

96829-58-2sc-203108
50 mg
$51.00
7
(1)

Inhibits gastrointestinal lipases, leading to decreased breakdown and absorption of dietary fats, which can influence lipid metabolism related to FAM57A.

Mevastatin (Compactin)

73573-88-3sc-200853
sc-200853A
10 mg
50 mg
$75.00
$175.00
18
(1)

Inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, potentially affecting the lipid environment of FAM57A.

Fenofibrate

49562-28-9sc-204751
5 g
$40.00
9
(1)

Activates peroxisome proliferator-activated receptor alpha (PPARα), leading to altered lipid metabolism that could indirectly affect FAM57A.

Gemfibrozil

25812-30-0sc-204764
sc-204764A
5 g
25 g
$65.00
$262.00
2
(2)

Another PPARα agonist, which modulates lipid metabolism and could influence FAM57A-related pathways.

Nicotinic Acid

59-67-6sc-205768
sc-205768A
250 g
500 g
$61.00
$122.00
1
(1)

Acts as an antilipolytic agent by inhibiting lipolysis in adipose tissue, which may impact the lipid substrates associated with FAM57A.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Inhibits lysosomal acid lipases, potentially affecting the degradation of lipids and indirectly influencing FAM57A's function.

Filipin III

480-49-9sc-205323
sc-205323A
500 µg
1 mg
$116.00
$145.00
26
(2)

Binds to cholesterol, disrupting lipid rafts and possibly affecting the localization or function of FAM57A within membrane domains.